Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Jun 4;16(6):e0252189.
doi: 10.1371/journal.pone.0252189. eCollection 2021.

Assessment of depressive symptoms in patients with COVID-19 during the second wave of epidemic in Myanmar: A cross-sectional single-center study

Ye Minn Htun  1 , Kyaw Thiha  2 , Aung Aung  3 , Nay Myo Aung  4 , Thet Wai Oo  5 , Pyae Sone Win  5 , Nay Hein Sint  6 , Kaung Myat Naing  6 , Aung Khant Min  1 , Kyaw Myo Tun  6 , Kyaw Hlaing  1
Affiliations
Clinical Trial

Assessment of depressive symptoms in patients with COVID-19 during the second wave of epidemic in Myanmar: A cross-sectional single-center study

Ye Minn Htun et al. PLoS One. .

Abstract

Background: Coronavirus disease 2019 (COVID-19) pandemic has had a great impact on every aspect of society. All countries launched preventive measures such as quarantine, lockdown, and physical distancing to control the disease spread. These restrictions might effect on daily life and mental health. This study aimed to assess the prevalence and associated factors of depressive symptoms in patients with COVID-19 at the Treatment Center.

Methods: A cross-sectional telephone survey was carried out at Hmawbi COVID-19 Treatment Center, Myanmar from December 2020 to January 2021. A total of 142 patients with COVID-19 who met the criteria were invited to participate in the study. A pre-tested Center for Epidemiologic Studies Depression Scale (CES-D) was used as a tool for depressive symptoms assessment. Data were analyzed by using binary logistic regression to identify associated factors of depressive symptoms. Adjusted odds ratio (AOR) with a 95% confidence interval (CI) was computed to determine the level of significance with a p < 0.05.

Results: The prevalence of depressive symptoms in patients with COVID-19 was 38.7%, with the means (± standard deviation, SD) subscale of somatic symptom, negative effect, and anhedonia were 4.64 (±2.53), 2.51 (± 2.12), and 5.01 (± 3.26), respectively. The patients with 40 years and older (AOR: 2.99, 95% CI: 1.36-6.59), < 4 of household size (AOR: 3.45, 95% CI: 1.46-8.15), ≤ 400,000 kyats of monthly family income (AOR: 2.38, 95% CI: 1.02-5.54) and infection to family members (AOR: 4.18, 95% CI: 1.74-10.07) were significant associated factors of depressive symptoms.

Conclusion: The high prevalence of depressive symptoms, approximately 40%, was found in patients with COVID-19 in the Treatment Center. Establishments of psychosocial supports, providing psychoeducation, enhancing the social contact with family and friends, and using credible source of information related COVID-19 would be integral parts of mental health services in COVID-19 pandemic situation.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al.. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. N Engl J Med. 2020;382(13):1199–207. doi: 10.1056/NEJMoa2001316 - DOI - PMC - PubMed
    1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al.. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33. doi: 10.1056/NEJMoa2001017 - DOI - PMC - PubMed
    1. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al.. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536–44. doi: 10.1038/s41564-020-0695-z - DOI - PMC - PubMed
    1. World Health Organization. Timeline of WHO’s response to COVID-19 Geneva: World Health Organization; 2020. [updated 2020 September 9; cited 2020 October 14]. Available from: https://www.who.int/news/item/29-06-2020-covidtimeline.
    1. World Health Organization. Coronavirus Disease (COVID-19) Dashboard Geneva, Switzerland: World Health Organization; 2020. [cited 2021 January 29]. Available from: https://covid19.who.int/.

Publication types